文献速递泌尿生殖与妇科肿瘤放疗消化道肿瘤放疗姑息放疗与转移瘤

女性生殖系统肿瘤患者放疗后继发性盆腔肿瘤的风险与生存结局:一项大型人群队列研究

Risk and survival outcomes of secondary pelvic neoplasm after radiotherapy in female patients with genital neoplasms: A large Population-Based cohort study.
PubMed 文献 · Radiother Oncol · 2024-11-07

该研究基于SEER数据库纳入1990至2015年间九家肿瘤中心的102,895例女性生殖系统肿瘤患者,比较放疗组25,774例与非放疗组77,121例继发性盆腔肿瘤的发生风险及生存结局。放疗组继发性盆腔肿瘤累积发生率为5.10%,非放疗组为3.42%;放疗组膀胱癌、结肠癌和直肠癌风险显著升高。发生膀胱癌的放疗组患者10年生存率显著低于原发性盆腔肿瘤患者(P=0.01)。

要点

  • 放疗组继发性盆腔肿瘤累积发生率为5.10%,非放疗组为3.42%。
  • 放疗组膀胱癌调整后HR为1.75(95%CI 1.43-2.14,P<0.05),结肠癌调整后HR为1.32(95%CI 1.16-1.49,P<0.05),直肠癌调整后HR为1.34(95%CI 1.10-1.65,P<0.05)。
  • 倾向性评分匹配后,放疗组发生膀胱癌的患者10年生存率显著低于原发性盆腔肿瘤患者(P=0.01)。

核心结论

  • 放疗被确定为女性生殖系统肿瘤患者发生继发性盆腔肿瘤的独立危险因素。
  • 接受放疗的女性生殖系统肿瘤患者发生继发性肿瘤(尤其是膀胱癌)的风险显著增加,且10年生存率降低。

研究设计与样本

  • 基于SEER数据库的队列研究,纳入1990至2015年间九家肿瘤中心的102,895例女性生殖系统肿瘤患者。
  • 放疗组25,774例,非放疗组77,121例;采用Fine-Gray竞争风险回归分析继发性盆腔肿瘤的发生轨迹,采用Kaplan-Meier法计算10年总生存率。

主要发现

  • 继发性盆腔肿瘤累积发生率放疗组为5.10%,非放疗组为3.42%。
  • 放疗组较非放疗组膀胱癌发生率显著升高(调整后HR 1.75,95%CI 1.43-2.14,P<0.05)。
  • 放疗组较非放疗组结肠癌发生率显著升高(调整后HR 1.32,95%CI 1.16-1.49,P<0.05)。
  • 放疗组较非放疗组直肠癌发生率显著升高(调整后HR 1.34,95%CI 1.10-1.65,P<0.05)。
  • 倾向性评分匹配后,放疗组发生膀胱癌的患者10年生存率显著低于原发性盆腔肿瘤患者(P=0.01)。

关键数值与推荐

  • 继发性盆腔肿瘤累积发生率:放疗组5.10% vs 非放疗组3.42%。
  • 膀胱癌:放疗组 vs 非放疗组调整后HR 1.75(95%CI 1.43-2.14,P<0.05)。
  • 结肠癌:放疗组 vs 非放疗组调整后HR 1.32(95%CI 1.16-1.49,P<0.05)。
  • 直肠癌:放疗组 vs 非放疗组调整后HR 1.34(95%CI 1.10-1.65,P<0.05)。
  • 倾向性评分匹配后放疗组膀胱癌患者10年生存率与原发性盆腔肿瘤患者比较P=0.01。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To investigate the impact of radiotherapy (RT) on the risk of secondary pelvic neoplasms (SPN) and the survival outcomes of patients following a diagnosis of female patients with genital neoplasm(FGN). MATERIALS AND METHODS: Utilizing SEER databases, this study involved 102,895 patients from nine oncology centers, spanning 1990 to 2015. We employed the Fine-Gray competing risks regression methodology to chart the trajectory of SPN development and used the Kaplan-Meier method to calculate the 10-year overall survival rates. RESULTS: This study included 25,774 patients in the RT group and 77,121 in the non-radiotherapy (NRT) group. The cumulative incidence rate of SPN was 5.10 % in the RT group and 3.42 % in the NRT group. The RT group showed a significantly higher incidence of bladder cancer (adjusted hazard ratio [HR]: 1.75; 95 % confidence interval [CI]: 1.43-2.14; P < 0.05), colon cancer (adjusted HR: 1.32; 95 % CI: 1.16-1.49; P < 0.05), and rectal cancer (adjusted HR: 1.34; 95 % CI: 1.10-1.65; P < 0.05) compared to the NRT group. After propensity score matching, patients in the RT group who developed bladder cancer had significantly reduced 10-year survival rates compared to patients with primary pelvic tumors (P = 0.01). CONCLUSION: RT is identified as an independent risk factor for the development of SPN in patients with FGN. Patients with FGN who undergo RT demonstrate a significant increase in the risk of developing secondary neoplasms, specifically bladder cancers, and experience a reduction in 10-year survival rates.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lyu YH, Liu JQ, Wang FH, et al. Risk and survival outcomes of secondary pelvic neoplasm after radiotherapy in female patients with genital neoplasms: A large Population-Based cohort study. Radiother Oncol. 2024. PMID: 39521276. doi:10.1016/j.radonc.2024.110595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。